SIGA Technologies, Inc.New York, NY United States
Company Description
SIGA Technologies is trying to put itself on the front lines of US biodefense efforts. The drug company has a number of development programs for vaccines, antivirals, and antibiotics for drug resistant infections; however, its main focus is on vaccines for bio-defense. The company's smallpox vaccine ST-246, which is intended both to prevent and treat the disease, has received Fast Track and Orphan Drug designations from the FDA. SIGA is also developing vaccines for use against hemorrhagic fevers and other infectious diseases and biothreats. Much of its work is done through funding from the
| 420 Lexington Ave., Ste. 408 | Phone: 212-672-9100 | http://www.siga.com |
| New York, NY 10170 | Fax: 212-697-3130 | 
Map This Company |
| United States |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
SIGA Technologies, Inc. Rankings
| Russell 2000 (June 2011) |
Executives
| 18 executives listed for SIGA Technologies, Inc.'s New York, NY location. | ||
| Chairman and CEO | Eric Rose | |
|---|---|---|
| EVP and CFO | Daniel Luckshire | |
| VP and Chief Scientific Officer | Dennis Hruby | |
Financials
| Company Type | Public - NASDAQ: SIGA Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 68 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on SIGA Technologies, Inc. now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
